Compare ESPR & VBNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESPR | VBNK |
|---|---|---|
| Founded | 2008 | 1980 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.9M | 606.0M |
| IPO Year | 2013 | 2016 |
| Metric | ESPR | VBNK |
|---|---|---|
| Price | $3.13 | $17.16 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 2 |
| Target Price | $8.75 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 16.9M | 71.5K |
| Earning Date | 05-07-2026 | 06-03-2026 |
| Dividend Yield | N/A | ★ 0.41% |
| EPS Growth | ★ 60.71 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,135,000.00 | N/A |
| Revenue This Year | N/A | $30.02 |
| Revenue Next Year | $12.81 | $27.30 |
| P/E Ratio | ★ N/A | $25.91 |
| Revenue Growth | ★ 21.31 | N/A |
| 52 Week Low | $0.76 | $10.10 |
| 52 Week High | $4.18 | $19.02 |
| Indicator | ESPR | VBNK |
|---|---|---|
| Relative Strength Index (RSI) | 70.76 | 47.46 |
| Support Level | $2.37 | $15.74 |
| Resistance Level | $3.18 | $17.17 |
| Average True Range (ATR) | 0.05 | 0.51 |
| MACD | 0.07 | -0.22 |
| Stochastic Oscillator | 96.38 | 5.76 |
Esperion Therapeutics Inc is a commercial-stage biopharmaceutical company currently focused on bringing new medicines to patients that address unmet medical needs. It has developed and is commercializing U.S. Food and Drug Administration, or FDA, approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (or CVD and are struggling with elevated low-density lipoprotein cholesterol, or LDL-C. The Company views its operations and manages its business in one operating segment, which is the business of researching, developing, and commercializing therapies for the treatment of patients with elevated LDL-C. The company depends almost entirely on the success of two products, the bempedoic acid tablet and the bempedoic acid/ezetimibe combination tablet.
VersaBank is a Schedule I Canadian bank that provides mainly commercial lending and banking services to select niche markets in Canada and the United States. Its products and services include credit assets, deposits, and cybersecurity services through its wholly owned subsidiary. The bank operates through four segments: Digital Banking Canada and Digital Banking USA, both using a business-to-business model with proprietary financial technology to serve underserved markets; DRTC, which provides cybersecurity services and banking and financial technology development; and Digital Meteor, which owns proprietary technology supporting next-generation digital assets, including Real Bank Deposit Tokens (RBDTs). The majority of revenue comes from Digital Banking.